Bladder Cancer
7 competing products in clinical development for Bladder Cancer.
Pipeline by Phase
Phase 1/24
Phase 22
Phase 31
All Products (7)
| Product | Company | Stage | Status | Hype |
|---|---|---|---|---|
| MK-3475 + ASG-22CE | Astellas Pharma | Phase 2 | Recruiting | 42 |
| Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin | Astellas Pharma | Phase 3 | Completed | 40 |
| Enfortumab vedotin | Astellas Pharma | Phase 1/2 | Recruiting | 39 |
| Enfortumab Vedotin + Pembrolizumab | Astellas Pharma | Phase 1/2 | Recruiting | 39 |
| Durvalumab + S-488210/S-488211 | Shionogi | Phase 1/2 | Recruiting | 39 |
| Enzalutamide | Astellas Pharma | Phase 2 | Terminated | 27 |
| Gemcitabine + E7389 + Cisplatin | Eisai | Phase 1/2 | Terminated | 24 |